Cancer Trials

  • Biospecimen s15-­01162

    This is a non-­interventional multicenter human research study in which we hope to better understand genetic and epigenetic changes that take place in T cells in Cutaneous T-­cell lymphoma (CTCL).

  • Biospecimens (MSK 06-107)

    This protocol allows MSK to collect and keep biospecimen samples in order to conduct research in the present and maintained for future research.

  • Bladder/Urothelial Cancer A031701

    This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

  • Blood Cancer CA056-025

    The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).

  • Breast Cancer - A012103

    This study seeks to compare the effect of pembrolizumab versus observation in patients with early-stage triple-negative breast cancer who have achieved a pathologic complete response after preoperative chemotherapy + pembrolizumab.

  • Breast Cancer - Trial to Minimize Non-Response to Aerobic Training (MSK 20-130)

    This study is designed to evaluate the cardiorespiratory fitness (CRF) response rate to different aerobic therapy (AT) doses in patients with post-treatment primary breast cancer.

  • Breast Cancer D926QC00001

    This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.

  • Breast Cancer NRG-BR009

    This study seeks to determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).

  • Cervical Cancer GOG-3043

    This is a randomized controlled trial to compare survival for patients who underwent robotic assisted laparoscopy versus open radical hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.

  • Colorectal Cancer - Microbiota Modulation of Chemotherapy-related Pain and Fatigue

    This research project was designed to better understand the persistent pain and fatigue after cancer treatment. Using a bio-omics approach, the study will be the first to longitudinally investigate the relationship among lifestyle factors and gut/plasma microbiome pattern, and to explore the dynamic changes of microbial genomes to predict pain and fatigue in CRC patients.

  • Endometrial Cancer (GYN POEM Trial)

    The purpose of this study is to learn how cancer-related distress and/or reproductive concerns affect a woman's decision to remove or preserve her ovaries during surgery for endometrial cancer.

  • Endometrial Cancer MSK 20-067

    This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.

  • Gastroesophageal Cancer - mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab (A022102)

    The study's purpose is to determine if overall survival is improved in patients who received mFOLFIRINOX +/- nivolumab in comparison to FOLFOX +/- nivolumab as first-line chemotherapy for metastatic gastroesophageal adenocarcinoma.

  • Gastrointestinal Cancer A022102

    This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma.

  • Gastrointestinal Cancer AMG 193 20230223

    The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers.

  • Gastrointestinal Cancer MSK 22-164

    This is a single-center, phase 2, 3-arm randomized controlled trial (RCT) study designed to evaluate the dose-response of aerobic training (AT) on treatment tolerability in patients with gastrointestinal (GI) cancers.

  • Genitourinary Cancer - GUIDANCE NRG GU010

    This study's aim is to identify whether or not intensifying or de-intensifying treatment for prostate cancer depending on genomic risk category will promote better health outcomes.

  • Genomic Profiling IMPACT (MSK 12-245)

    The purpose of this genomic profiling study is to determine whether certain genes in cancer may be abnormal.

  • GI - 1002-CL-0101: A Study of ASP1002 in Adults for Treatment of Solid Tumors

    A Study of ASP1002 in Adults for Treatment of Solid Tumors

  • GU - PIVOT-006

    This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.

  • GU - S2312

    This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic).

  • Gyn-onc - GOG-3107 (RAINFOL-OV2/GCT1184-02/PRO1184-002/ENGOT-OV86)

    The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer.

  • Gyn-onc - GS-US-682-6769/GOG-3104/ENGOT-en26

    The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC).

  • Head & Neck - MSK 24-200

    The researchers are doing this study to find out if a personalized approach to chemoradiation therapy (which may include a lower dose of radiation) is as effective as the standard chemoradiation therapy in people with HPV-positive throat cancer.

  • Hospice - Home Hospice Experience with Telemedicine (ONC-NTX-HOSPICE-20-003)

    Integration of the oncologist in the development of the patient's end-of-life care plan and medical decision-making process ("shared care") during the transition to hospice may remove known barriers to end-of-life care and impact the patient, family and care team's experience. This study serves to assess the feasibility of implementing this shared care model in a single-center, community-based hospital system, and measure the impact of the use of telemedicine to integrate the oncologist in the hospice setting.

  • Liver Cancer ML44719

    This is a Phase II, open-label, multicohort, multicenter study in participants with unresectable, locally advanced, or metastatic hepatocellular carcinoma (HCC) who have Child-Pugh B7 or B8 liver cirrhosis and have received no prior systemic therapy in this treatment setting. The study is designed to non-comparatively evaluate the safety and efficacy of atezolizumab plus bevacizumab (Cohort A) or atezolizumab monotherapy (Cohort B) in this population.

  • Lung Cancer - EA5182

    The primary objective of this trial is to evaluate progression-free survival (PFS) of osimertinib (AZD9291) and bevacizumab versus osimertinib (AZD9291) alone as first-line treatment for patients with metastatic EGFR-mutant lung cancers.

  • Lung Cancer - Early Detection of Tobacco-Associated Lung Cancer (MSK 19-466)

    Lung cancer is the only tobacco-related malignancy that currently has an effective, widely recommended screening test: low dose CT (LDCT) of the chest. The purpose of this study is to evaluate how a combination of biomarkers acquired from various body fluids can perform compared to the current standard chest LDCT screening test.

  • Lung Cancer - Modulation of Lung Immune Responses to Viral Infection (JAX)

    The purpose of this study is to examine interactions between lung immune cells and environmental microbial factors to understand immunological mechanisms.

  • Lung Cancer - MSK 21-465

    This study is to see whether or not intervention before progression in certain patients can produce better outcomes for these patients.

  • Melanoma - MSK 23-098

    The purpose of this trial is to see how well the vaccine IO102/IO103 works in people with inoperable melanoma. People in this study will get IO102/IO103 with two drugs: nivolumab and relatlimab. It is hoped that combining the vaccine with these anti-cancer medications will boost the immune system to fight cancer.

  • Melanoma - R3767-ONC-2208: A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1

    This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with cemiplimab alone.

  • Multiple Cancer Tumor Types - TAPUR

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

  • Multiple Myeloma EAA181 (EQUATE)

    Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

  • Multiple Tumor Types - Moonshot Biobank 10323

    The Cancer Moonshot Biobank was started by the National Cancer Institute to help researchers better understand and treat cancer. The Moonshot Biobank will ask cancer patients across the United States to donate biospecimens (blood and small pieces of tissue removed during medical procedures) and associated health information.

  • Multiple Tumor Types - VMO-01C: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymph

    This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

  • Neurologic Cancer MSK 20-091

    The purpose of this study is to assess the safety and effectiveness of combining three drugs to treat people with an IDH-mutant glioma that came back after chemotherapy or surgery.

  • Neuro-onc - NRG-BN013

    This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain.

  • Ovarian Cancer NRG-CC008

    This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1 mutations.

  • Prostate Cancer - PREDICT-RT (NRG-GU009)

    Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*) *Prostate RNA Expression/Decipher To Individualize Concurrent Therapy with Radiation

  • Rectal Cancer - Janus (A022104)

    This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course chemoradiation in patients with stage II-III rectal cancer.

  • Thoracic - LEADER

    This collaborative screening protocol, developed by the Lung Cancer Mutation Consortium (LCMC) and supported by the Thoracic Surgery Oncology Group (TSOG), is designed to determine the feasibility of comprehensive molecular profiling to detect actionable oncogenic drivers in patients with suspected early stage lung cancers scheduled to undergo biopsies to establish the diagnosis of lung cancer.

  • Thoracic - S2414

    This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer.

  • Thoracic Cancer - LUNGMAP

    This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (S1400).

  • Thoracic Cancer MSK 22-133

    This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational treatment, in this case stereotactic radiation, to learn whether this treatment works in treating a specific disease. "Investigational" means that the treatment is being studied.

Search This Section